CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease
VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...
Tag: GvHD
© Copyright 2022 publicwire.com